Subscribe
Conference Correspondent
Management of patients with lymph node-positive (high-risk) stage III melanoma is a clinical challenge today. In Europe, high-dose interferon alpha-2b is approved for use in this setting. In the United States, both high-dose interferon alpha-2b and pegylated interferon alpha-2b are registered for patients with high-risk stage III melanoma.
Cell-based therapies with lymphocytes and antigen-presenting cells are promising approaches in the context of cancer immunotherapy.
Although more than 80% of adults with acute lymphoblastic leukemia (ALL) respond to induction chemotherapy with complete clinical remission, up to 50% of these patients relapse with chemoresistant disease.
Ipilimumab (IPI), an anti-CTLA-4 antibody, has become a standard option in the management of advanced melanoma after demonstrating durable responses and improved overall survival (OS).
Dabrafenib (D), trametanib (T), and ipilimumab (IPI) are each indicated for treatment of patients with metastatic melanoma (MM), with D and T approved specifically in BRAFV600 mutation-positive unresectable melanoma or MM. D and T can also be safely combined in these patients, with enhanced response rates compared with monotherapy.
The majority of women diagnosed with ovarian epithelial cancer (80%) relapse after first-line platinum- and taxane-based chemotherapy. Clinical recurrences within 6 months of completion of platinum-containing therapy are described as platinum-refractory or platinum-resistant.
News articles and press releases that focus on this year’s annual ASCO meeting include a plethora of predictions and analyses regarding immuno-oncology agents, including immune checkpoint inhibitors (ICIs) and therapeutic vaccines. Phrases like “new paradigm in cancer treatment,” and adjectives including “prominent”, “hot”, and “promising” pepper these headlines and commentaries.
Ipilimumab (IPI), a fully human anti-CTLA-4 monoclonal antibody, is approved as a single agent for patients with metastatic melanoma (MM) on the basis of increased overall survival compared with an experimental tumor vaccine (glycoprotein 100).
Uveal melanoma is the most common primary intraocular malignancy in adults. In the United States, approximately 4.3 new cases are diagnosed per 1 million people, with no variation based on geographic latitude.
Metastatic transitional cell or urothelial bladder cancer (UBC) is associated with a poor prognosis and limited treatment options. Approximately 70% to 80% of patients with newly diagnosed bladder cancer present with superficial bladder tumors in which prognosis varies based on tumor grade.
Page 1 of 3
Results 1 - 10 of 22
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology